

FY26

PRELIMINARY RESULTS

Steven Lydeamore - CEO

NASDAQ: IMRN
ASX: IMC

SAFE HARBOR STATEMENT

Certain statements made in this presentation are forward-looking statements and are based on Immuron's current expectations, estimates and projections. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements.

Although Immuron believes the forward-looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron's control, including those risks or uncertainties inherent in the process of both developing and commercializing technology. As a result, actual results could materially differ from those expressed or forecasted in the forward-looking statements.

The forward-looking statements made in this presentation relate only to events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority.

FY2026 results in this presentation are subject to audit review.

FY26 Financial Achievements

Global Sales Revenue
$7.7m
Up 6%

Australian Sales Revenue
$5.8m
Up 10%

United States Sales Revenue
$1.8m
Up 7%
Up 13% in $USD

Gross Profit Margin
64.5%
0.9% decline

Net Profit
$(3.8)m
$1.4m improvement

Cash
$9.0m
$6.2m[1] improvement

1. $3.0 million was held in Term Deposits on 30 June 2025 (30 June 2026: Nil)

FY26 Clinical Achievements and Operational Highlights

FDA approval
IMM-529
IND

Travelan®
n=851 trial
completed

New U.S.
Department of
Defense
subaward

New product launch
in Australia

ProIBS

Strategic reset
aimed at
profitability and
reduced cash burn

Engaged Pullan
Consulting to
support partnering
IMM-529

PULLAN
CONSULTING

FY27 Outlook

Continued Travelan® sales growth

Portfolio expansion

Geographic sales expansion

Partnering update for IMM-529

Continued improvement in profitability and reduced cash burn

Cash to fund operations through FY27 – FY28

STEVEN LYDEAMORE
CHIEF EXECUTIVE OFFICER
IMMURON LIMITED

CONTACT INFORMATION:

EMAIL: STEVE@IMMURON.COM

PHONE: AUSTRALIA: +61 438 027 172

IMMURON INVESTOR HUB

COMMUNICATION AND CONTENT INCLUDING ANNOUNCEMENTS AND CORPORATE RESEARCH